| Time |
Topic |
| 09:00-09:10 |
Welcome Remarks |
이사장 이정언(삼성서울병원) |
| 09:10-10:40 |
Session I: Hormone Receptor-Positive Breast Cancer |
이정언(삼성서울병원) |
| 09:10-09:35 |
Navigating Adjuvant Targeted Combinations in High risk HR+ patients: Positioning CDK4/6 Inhibitors, PARP inhibitor, and Emerging SERDs |
윤창익(서울성모병원) |
| 09:35-10:05 |
Novel Agents Targeting the ER and PI3K–AKT–mTOR Pathway in Metastatic Breast Cancer |
홍문기(용인세브란스병원) |
| 10:05-10:30 |
Antibody–Drug Conjugates in HR-Positive Metastatic Breast Cancer |
양예원(충북대학교병원) |
| 10:30-10:40 |
Discussion |
|
| 10:40-10:50 |
Coffee Break |
| 10:50-12:15 |
Session II: HER2-Positive Breast Cancer |
이경은(이대목동병원) |
| 10:50-11:15 |
Risk-Adaptive Perioperative Strategies in Early HER2+ Breast Cancer |
한애리(원주세브란스병원) |
| 11:15-11:40 |
Current Treatment and Toxicity Management in Metastatic HER2+ Breast Cancer |
김주원(고대안암병원) |
| 11:40-12:05 |
Emerging First-Line Treatment Options in Metastatic HER2-Positive Breast Cancer |
전영경(양산부산대병원) |
| 12:05-12:15 |
Discussion |
|
| 12:15-13:20 |
Lunch |
| 13:20-14:45 |
Session III: Triple-Negative Breast Cancer |
박인혜(고대구로병원) |
| 13:20-13:45 |
Risk Stratification and Tailored Treatment Strategies in Early TNBC |
이장희(이대목동병원) |
| 13:45-14:10 |
Current Treatment and Toxicity Management in Metastatic TNBC |
나지현(울산대학교병원) |
| 14:10-14:35 |
Emerging First-Line Treatment Options in Metastatic Triple-Negative Breast Cancer |
채희정(분당서울대병원) |
| 14:35-14:45 |
Discussion |
|
| 14:45-15:00 |
Coffee Break |
| 15:00-16:25 |
Session IV: Future perspective |
박민호(화순전남대병원) |
| 15:00-15:25 |
Innovating Oncology Practice: AI-based Prediction of Treatment Response (pCR) and Toxicity Monitoring |
차윤진(강남세브란스병원) |
| 15:25-15:50 |
Beyond Imaging: The Role of Liquid Biopsy (ctDNA/MRD) in post-treatment monitoring |
김지선(서울아산병원) |
| 15:50-16:15 |
Surgical De-escalation in the Era of High pCR: Is Omission of Surgery the Next Frontier? |
정지정(삼성서울병원) |
| 16:15-16:25 |
Discussion |
|
| 16:25-16:35 |
Closing Remark |
회장 김태현(부산백병원) |
